AIMS/HYPOTHESIS: TNF-alpha levels are increased in obesity and type 2 diabetes. The regulation of TNF-alpha converting enzyme (TACE) and its inhibitor, tissue inhibitor of metalloproteinase 3 (TIMP3), in human type 2 diabetes is unknown. METHODS: We examined TACE/TIMP3 regulation: (1) in lean and obese normal glucose tolerant (NGT) individuals and in type 2 diabetes patients; (2) following 6 h of lipid/saline infusion in NGT individuals; and (3) in cultured human myotubes from lean NGT individuals incubated with palmitate. Insulin sensitivity was assessed by a euglycaemic clamp and TACE/TIMP3 was evaluated by confocal microscopy, RT-PCR, western blotting and an in vitro activity assay. Circulating TNF-alpha, TNF-alpha-receptor 1 (TNFR1), TNF-alpha-receptor 2 (TNFR2), IL-6 receptor (IL-6R), vascular cell adhesion molecule (VCAM) and intercellular adhesion molecule (ICAM) levels were evaluated. RESULTS: TIMP3 levels were reduced and TACE enzymatic activity was increased in type 2 diabetes skeletal muscle. TACE expression, and TACE, TNF-alpha, TNFR1 and IL-6R levels were increased in type 2 diabetes, and positively correlated with insulin resistance. A 6 h lipid infusion into NGT individuals decreased insulin-stimulated glucose metabolism by 25% with increased TACE, decreased expression of the gene encoding TIMP3 and increased IL-6R release. Palmitate induced a dramatic reduction of TIMP3 and increased the TACE/TIMP3 ratio in cultured myotubes. CONCLUSIONS/ INTERPRETATION: TACE activity was increased in skeletal muscle of obese type 2 diabetes patients and in lipid-induced insulin resistance. We propose that dysregulation of membrane proteolysis by TACE/TIMP3 of TNF-alpha and IL-6R is an important factor for the development of skeletal muscle insulin resistance in obese type 2 diabetes patients by a novel autocrine/paracrine mechanism.
AIMS/HYPOTHESIS: TNF-alpha levels are increased in obesity and type 2 diabetes. The regulation of TNF-alpha converting enzyme (TACE) and its inhibitor, tissue inhibitor of metalloproteinase 3 (TIMP3), in humantype 2 diabetes is unknown. METHODS: We examined TACE/TIMP3 regulation: (1) in lean and obese normal glucose tolerant (NGT) individuals and in type 2 diabetespatients; (2) following 6 h of lipid/saline infusion in NGT individuals; and (3) in cultured human myotubes from lean NGT individuals incubated with palmitate. Insulin sensitivity was assessed by a euglycaemic clamp and TACE/TIMP3 was evaluated by confocal microscopy, RT-PCR, western blotting and an in vitro activity assay. Circulating TNF-alpha, TNF-alpha-receptor 1 (TNFR1), TNF-alpha-receptor 2 (TNFR2), IL-6 receptor (IL-6R), vascular cell adhesion molecule (VCAM) and intercellular adhesion molecule (ICAM) levels were evaluated. RESULTS:TIMP3 levels were reduced and TACE enzymatic activity was increased in type 2 diabetes skeletal muscle. TACE expression, and TACE, TNF-alpha, TNFR1 and IL-6R levels were increased in type 2 diabetes, and positively correlated with insulin resistance. A 6 h lipid infusion into NGT individuals decreased insulin-stimulated glucose metabolism by 25% with increased TACE, decreased expression of the gene encoding TIMP3 and increased IL-6R release. Palmitate induced a dramatic reduction of TIMP3 and increased the TACE/TIMP3 ratio in cultured myotubes. CONCLUSIONS/ INTERPRETATION:TACE activity was increased in skeletal muscle of obese type 2 diabetespatients and in lipid-induced insulin resistance. We propose that dysregulation of membrane proteolysis by TACE/TIMP3 of TNF-alpha and IL-6R is an important factor for the development of skeletal muscle insulin resistance in obese type 2 diabetespatients by a novel autocrine/paracrine mechanism.
Authors: Jerzy Ostrowski; Karolina Klimek-Tomczak; Lucjan S Wyrwicz; Michal Mikula; Daniel S Schullery; Karol Bomsztyk Journal: J Biol Chem Date: 2004-10-13 Impact factor: 5.157
Authors: A Amour; P M Slocombe; A Webster; M Butler; C G Knight; B J Smith; P E Stephens; C Shelley; M Hutton; V Knäuper; A J Docherty; G Murphy Journal: FEBS Lett Date: 1998-09-11 Impact factor: 4.124
Authors: Diane M Jaworski; Olga Sideleva; Holly M Stradecki; Garret D Langlois; Aida Habibovic; Basanthi Satish; William G Tharp; James Lausier; Kyla Larock; Thomas L Jetton; Mina Peshavaria; Richard E Pratley Journal: Endocrinology Date: 2011-02-01 Impact factor: 4.736
Authors: Teresa Vanessa Fiorentino; Francesca Casiraghi; Alberto M Davalli; Giovanna Finzi; Stefano La Rosa; Paul B Higgins; Gregory A Abrahamian; Alessandro Marando; Fausto Sessa; Carla Perego; Rodolfo Guardado-Mendoza; Subhash Kamath; Andrea Ricotti; Paolo Fiorina; Giuseppe Daniele; Ana M Paez; Francesco Andreozzi; Raul A Bastarrachea; Anthony G Comuzzie; Amalia Gastaldelli; Alberto O Chavez; Eliana S Di Cairano; Patrice Frost; Livio Luzi; Edward J Dick; Glenn A Halff; Ralph A DeFronzo; Franco Folli Journal: JCI Insight Date: 2019-10-17
Authors: P G F Quaresma; N Reencober; T M Zanotto; A C Santos; L Weissmann; A H B de Matos; I Lopes-Cendes; F Folli; M J A Saad; P O Prada Journal: Int J Obes (Lond) Date: 2015-07-31 Impact factor: 5.095
Authors: Devjit Tripathy; Giuseppe Daniele; Teresa V Fiorentino; Zandra Perez-Cadena; Alberto Chavez-Velasquez; Subhash Kamath; Paolo Fanti; Christopher Jenkinson; Francesco Andreozzi; Massimo Federici; Amalia Gastaldelli; Ralph A Defronzo; Franco Folli Journal: Diabetologia Date: 2013-06-30 Impact factor: 10.122
Authors: Laura Montefusco; Moufida Ben Nasr; Francesca D'Addio; Cristian Loretelli; Antonio Rossi; Ida Pastore; Giuseppe Daniele; Ahmed Abdelsalam; Anna Maestroni; Marco Dell'Acqua; Elio Ippolito; Emma Assi; Vera Usuelli; Andy Joe Seelam; Roberta Maria Fiorina; Enrica Chebat; Paola Morpurgo; Maria Elena Lunati; Andrea Mario Bolla; Giovanna Finzi; Reza Abdi; Joseph V Bonventre; Stefano Rusconi; Agostino Riva; Domenico Corradi; Pierachille Santus; Manuela Nebuloni; Franco Folli; Gian Vincenzo Zuccotti; Massimo Galli; Paolo Fiorina Journal: Nat Metab Date: 2021-05-25